ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
27.45
+0.86 (3.23%)
Nov 22, 2024, 4:00 PM EST - Market closed
ArriVent BioPharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -81.05 | -69.33 | -36.91 | -68.81 |
| Asset Writedown & Restructuring Costs | - | - | - | 57.21 |
| Stock-Based Compensation | 2.58 | 0.9 | 0.42 | 0.07 |
| Change in Accounts Payable | 0.41 | 1.38 | 2.8 | 0.39 |
| Change in Other Net Operating Assets | 9.09 | 11.22 | -9.95 | -5.65 |
| Operating Cash Flow | -68.97 | -55.84 | -43.63 | -16.78 |
| Sale (Purchase) of Intangibles | - | - | - | -53.33 |
| Investing Cash Flow | 25 | - | - | -53.33 |
| Total Debt Issued | - | - | - | 0.27 |
| Total Debt Repaid | - | - | - | -0.27 |
| Issuance of Common Stock | 186.81 | 0.35 | 0.02 | 0 |
| Other Financing Activities | -1.34 | -2.41 | - | - |
| Financing Cash Flow | 185.47 | 42.86 | 169.72 | 119.82 |
| Net Cash Flow | 141.5 | -12.98 | 126.09 | 49.71 |
| Free Cash Flow | -68.97 | -55.84 | -43.63 | -16.78 |
| Free Cash Flow Per Share | -2.91 | -26.08 | -34.16 | -23.60 |
| Levered Free Cash Flow | -46.97 | -32.8 | -29.81 | - |
| Unlevered Free Cash Flow | -46.97 | -32.8 | -29.81 | - |
| Change in Net Working Capital | -9.03 | -12.92 | 7.16 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.